Dong-A ST Company Description

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products and medical devices worldwide.

It offers various ethical drugs, including Closerin for active pulmonary and extra-pulmonary tuberculosis; Dulastin and Leucostim for neutropenia in patients receiving myelosuppressive chemotherapy; Eporon for anemia associated with chronic renal failure; Gemcit for non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin for infertility and annovulation; Growtropin II for growth failure due to an inadequate secretion of growth hormone and idiopathic short stature; Mainta for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel for breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma; Motilitone for use in functional dyspepsia treatment; Stillen for the treatment of gastritis; Suganon for diabetes treatment; Terizidone for active pulmonary and extra-pulmonary tuberculosis; and Zydena for erectile dysfunction treatment.

The company also provides licensed-in and licensed-out drugs; and medical devices, which cover high technology medical devices, custom made products, and sets of artificial cardiac circuits for use in open-heart surgery.

Dong-A ST Co., Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.

Dong-A ST Co., Ltd.

Country	South Korea
Founded	1932
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
CEO	Jae-Hun Jung

Contact Details

Address: 64 Cheonhodaero Seoul South Korea
Phone	82 2 920 8111

Stock Details

Ticker Symbol	170900
Exchange	Korea Stock Exchange
Fiscal Year	January - December
Reporting Currency	KRW
ISIN Number	KR7170900005
SIC Code	2834

Key Executives

Name	Position
Jae-Hun Jung	Chief Executive Officer, President and Director
Jae-Hong Park	President and Director
GyuHong Jo	Managing Director
SunJong So	Managing Director
Yu-Seok Shin	Managing Director
SeongAe Yoon	Head
DaeWoo Lee	Executive Director